Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. CART

Go back to Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat

Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

August 2, 2018 7:05 AM EDT

Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019

Conference call scheduled for 8:30 a.m. ET today

NEW YORK, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver... More